An MVA vaccine overcomes tolerance to human p53 in mice and humans

Guang Yun Song, Glen Gibson, Wahajul Haq, Eric C C Huang, Tumul Srivasta, Monica Hollstein, Pirouz Daftarian, Zhongde Wang, Don Diamond, Joshua D I Ellenhorn

Research output: Contribution to journalArticle

Abstract

Background: The cellular regulatory protein p53 is overexpressed by almost 50% of all malignancies making it an attractive target for a vaccine approach to cancer. A number of immunotherapy approaches targeting p53 have been evaluated successfully in murine models, but translation of these preclinical findings to the clinic has been unsuccessful. Prior studies in our laboratory employing murine models demonstrated that a modified vaccinia virus Ankara (MVA) vaccine expressing murine p53 could stimulate p53 specific immunity. Systemic administration of the MVA vaccine was able to effect the rejection of established tumors. To better understand the immunologic mechanisms that underlie the vaccine function of human p53, we utilized a murine model in which the murine germ line copy of p53 was replaced with a modified human one. These mice, referred to as Hupki, were evaluated as a tolerant model to explore the capacity of MVA expressing human p53 to overcome tolerance and reject human p53-expressing tumors. Results: MVAp53 immunization of Hupki mice resulted in the generation of p53-specific CD8+ T cells and the rejection of a highly aggressive murine mammary carcinoma cell line 4T1(H-2d) transfected with human p53 (4T1p53). An immunologic correlate of tumor protection was evaluated utilizing an overlapping peptide library spanning the full length of human p53. This reagent was also used in combination with MVAp53 to stimulate p53-specific CD8+ T cell responses in cancer patients. Conclusion: These studies demonstrate the potential of MVAp53 to overcome tolerance to p53 for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)1193-1205
Number of pages13
JournalCancer Immunology Immunotherapy
Volume56
Issue number8
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Vaccinia virus
Vaccines
Neoplasms
Immunotherapy
T-Lymphocytes
Peptide Library
Germ Cells
Immunity
Immunization
Breast Neoplasms
Cell Line
Proteins

Keywords

  • Animal models of cancer
  • Cancer vaccines
  • Immune response to cancer
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Song, G. Y., Gibson, G., Haq, W., Huang, E. C. C., Srivasta, T., Hollstein, M., ... Ellenhorn, J. D. I. (2007). An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunology Immunotherapy, 56(8), 1193-1205. https://doi.org/10.1007/s00262-006-0270-3

An MVA vaccine overcomes tolerance to human p53 in mice and humans. / Song, Guang Yun; Gibson, Glen; Haq, Wahajul; Huang, Eric C C; Srivasta, Tumul; Hollstein, Monica; Daftarian, Pirouz; Wang, Zhongde; Diamond, Don; Ellenhorn, Joshua D I.

In: Cancer Immunology Immunotherapy, Vol. 56, No. 8, 08.2007, p. 1193-1205.

Research output: Contribution to journalArticle

Song, GY, Gibson, G, Haq, W, Huang, ECC, Srivasta, T, Hollstein, M, Daftarian, P, Wang, Z, Diamond, D & Ellenhorn, JDI 2007, 'An MVA vaccine overcomes tolerance to human p53 in mice and humans', Cancer Immunology Immunotherapy, vol. 56, no. 8, pp. 1193-1205. https://doi.org/10.1007/s00262-006-0270-3
Song GY, Gibson G, Haq W, Huang ECC, Srivasta T, Hollstein M et al. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunology Immunotherapy. 2007 Aug;56(8):1193-1205. https://doi.org/10.1007/s00262-006-0270-3
Song, Guang Yun ; Gibson, Glen ; Haq, Wahajul ; Huang, Eric C C ; Srivasta, Tumul ; Hollstein, Monica ; Daftarian, Pirouz ; Wang, Zhongde ; Diamond, Don ; Ellenhorn, Joshua D I. / An MVA vaccine overcomes tolerance to human p53 in mice and humans. In: Cancer Immunology Immunotherapy. 2007 ; Vol. 56, No. 8. pp. 1193-1205.
@article{030690b34ace483a93134be8602d0d8b,
title = "An MVA vaccine overcomes tolerance to human p53 in mice and humans",
abstract = "Background: The cellular regulatory protein p53 is overexpressed by almost 50{\%} of all malignancies making it an attractive target for a vaccine approach to cancer. A number of immunotherapy approaches targeting p53 have been evaluated successfully in murine models, but translation of these preclinical findings to the clinic has been unsuccessful. Prior studies in our laboratory employing murine models demonstrated that a modified vaccinia virus Ankara (MVA) vaccine expressing murine p53 could stimulate p53 specific immunity. Systemic administration of the MVA vaccine was able to effect the rejection of established tumors. To better understand the immunologic mechanisms that underlie the vaccine function of human p53, we utilized a murine model in which the murine germ line copy of p53 was replaced with a modified human one. These mice, referred to as Hupki, were evaluated as a tolerant model to explore the capacity of MVA expressing human p53 to overcome tolerance and reject human p53-expressing tumors. Results: MVAp53 immunization of Hupki mice resulted in the generation of p53-specific CD8+ T cells and the rejection of a highly aggressive murine mammary carcinoma cell line 4T1(H-2d) transfected with human p53 (4T1p53). An immunologic correlate of tumor protection was evaluated utilizing an overlapping peptide library spanning the full length of human p53. This reagent was also used in combination with MVAp53 to stimulate p53-specific CD8+ T cell responses in cancer patients. Conclusion: These studies demonstrate the potential of MVAp53 to overcome tolerance to p53 for cancer immunotherapy.",
keywords = "Animal models of cancer, Cancer vaccines, Immune response to cancer, p53",
author = "Song, {Guang Yun} and Glen Gibson and Wahajul Haq and Huang, {Eric C C} and Tumul Srivasta and Monica Hollstein and Pirouz Daftarian and Zhongde Wang and Don Diamond and Ellenhorn, {Joshua D I}",
year = "2007",
month = "8",
doi = "10.1007/s00262-006-0270-3",
language = "English (US)",
volume = "56",
pages = "1193--1205",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - An MVA vaccine overcomes tolerance to human p53 in mice and humans

AU - Song, Guang Yun

AU - Gibson, Glen

AU - Haq, Wahajul

AU - Huang, Eric C C

AU - Srivasta, Tumul

AU - Hollstein, Monica

AU - Daftarian, Pirouz

AU - Wang, Zhongde

AU - Diamond, Don

AU - Ellenhorn, Joshua D I

PY - 2007/8

Y1 - 2007/8

N2 - Background: The cellular regulatory protein p53 is overexpressed by almost 50% of all malignancies making it an attractive target for a vaccine approach to cancer. A number of immunotherapy approaches targeting p53 have been evaluated successfully in murine models, but translation of these preclinical findings to the clinic has been unsuccessful. Prior studies in our laboratory employing murine models demonstrated that a modified vaccinia virus Ankara (MVA) vaccine expressing murine p53 could stimulate p53 specific immunity. Systemic administration of the MVA vaccine was able to effect the rejection of established tumors. To better understand the immunologic mechanisms that underlie the vaccine function of human p53, we utilized a murine model in which the murine germ line copy of p53 was replaced with a modified human one. These mice, referred to as Hupki, were evaluated as a tolerant model to explore the capacity of MVA expressing human p53 to overcome tolerance and reject human p53-expressing tumors. Results: MVAp53 immunization of Hupki mice resulted in the generation of p53-specific CD8+ T cells and the rejection of a highly aggressive murine mammary carcinoma cell line 4T1(H-2d) transfected with human p53 (4T1p53). An immunologic correlate of tumor protection was evaluated utilizing an overlapping peptide library spanning the full length of human p53. This reagent was also used in combination with MVAp53 to stimulate p53-specific CD8+ T cell responses in cancer patients. Conclusion: These studies demonstrate the potential of MVAp53 to overcome tolerance to p53 for cancer immunotherapy.

AB - Background: The cellular regulatory protein p53 is overexpressed by almost 50% of all malignancies making it an attractive target for a vaccine approach to cancer. A number of immunotherapy approaches targeting p53 have been evaluated successfully in murine models, but translation of these preclinical findings to the clinic has been unsuccessful. Prior studies in our laboratory employing murine models demonstrated that a modified vaccinia virus Ankara (MVA) vaccine expressing murine p53 could stimulate p53 specific immunity. Systemic administration of the MVA vaccine was able to effect the rejection of established tumors. To better understand the immunologic mechanisms that underlie the vaccine function of human p53, we utilized a murine model in which the murine germ line copy of p53 was replaced with a modified human one. These mice, referred to as Hupki, were evaluated as a tolerant model to explore the capacity of MVA expressing human p53 to overcome tolerance and reject human p53-expressing tumors. Results: MVAp53 immunization of Hupki mice resulted in the generation of p53-specific CD8+ T cells and the rejection of a highly aggressive murine mammary carcinoma cell line 4T1(H-2d) transfected with human p53 (4T1p53). An immunologic correlate of tumor protection was evaluated utilizing an overlapping peptide library spanning the full length of human p53. This reagent was also used in combination with MVAp53 to stimulate p53-specific CD8+ T cell responses in cancer patients. Conclusion: These studies demonstrate the potential of MVAp53 to overcome tolerance to p53 for cancer immunotherapy.

KW - Animal models of cancer

KW - Cancer vaccines

KW - Immune response to cancer

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=34248531439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248531439&partnerID=8YFLogxK

U2 - 10.1007/s00262-006-0270-3

DO - 10.1007/s00262-006-0270-3

M3 - Article

C2 - 17219151

AN - SCOPUS:34248531439

VL - 56

SP - 1193

EP - 1205

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -